Tender Overview
The Indian Army under the Department Of Military Affairs issues a medicines procurement tender covering 15 listed pharmaceutical products, including common tablets and suspensions such as Paracetamol 650 mg, Vitamin B complex formulations, Calcium carbonate 500 mg with Vitamin D3, Gliclazide XR 60 mg, Thyroxin variants, Metronidazole 400 mg, Furosemide/Spironolactone, Ondansetron 8 mg, Methylcobalamin 1500 mcg, Sucralfate suspension, Ademetionine 400 mg, and Micronised Purified Flavonoid. The scope appears to be supply across multiple SKUs to support medical logistics, without specified quantities or estimated value. Unique aspects include a formal option clause enabling up to 25% quantity variation at contracted rates and a structured delivery timeline linked to the last delivery order date. The tender emphasizes supplier compliance with extension mechanics while maintaining delivery discipline in a defense context. This procurement opportunity requires bidders to align with military procurement norms and ensure item-level traceability and quality.
Technical Specifications & Requirements
- Product/service names: 15 pharmaceutical items as listed in the BoQ/Title (e.g., Paracetamol 650 mg, Cap B Complex, Calcium carbonate 500 mg + Vitamin D3 500 mg, Gliclazide XR 60 mg, Thyroxine sodium variants, Metronidazole 400 mg, Furosemide + Spironolactone, Ondansetron 8 mg, Methylcobalamin 1500 mcg, Sucralfate suspension, Ademetionine 400 mg, Micronised purified flavonoid).
- BoQ status: Not populated with explicit quantities (N/A), indicating centralized bidding for a bundle of medicines rather than per-item quantity disclosure.
- Delivery terms: Delivery period related to last date of original/extended delivery order; option clause allows up to 25% quantity variation during contract and extension rules with minimum 30 days additional time.
- Standards and compliance: Not specified; bidders should infer standardization and GMP alignment via government procurement expectations and ISI/ISO considerations where applicable.
- Financials: No explicit estimated value or EMD amount disclosed in data; bidders must treat as unpriced until tender documents reveal financial terms.
- Experience: No explicit technical experience requirements disclosed in the provided data; bidders should prepare typical pharmaceutical supply credentials and defense-grade compliance.
- Delivery location: Not specified in provided data; bidders should await official tender documents for precise distribution centers and site coordinates.
- Quality and testing: No explicit testing standards stated; bidders should propose standard pharmaceutical QA processes to meet defense sector expectations.
Terms, Conditions & Eligibility
- Quantity option: Up to 25% increase/decrease in bid quantity at contract placement; further adjustment permitted during contract currency.
- Delivery timeline: Commences from the last date of original delivery order; extended time calculated as (Additional quantity ÷ Original quantity) × Original delivery period, minimum 30 days.
- Compliance obligation: Bidders must adhere to option clause and delivery calculations as specified; non-compliance may affect award.
- Documentation: Terms imply standard bid submission materials for pharmaceutical suppliers; exact list to be confirmed in buyer’s tender documents.
- Penalties: No explicit LD or warranty terms listed in provided data; refer to full tender terms for penalties and performance bonds.
- Confidentiality and security: Not specified in data; defense procurement typically requires secure handling and chain-of-custody for medicines.
- Inspection and acceptance: Not detailed here; anticipate standard government procurement inspection on delivery.
- Payment terms: Not specified in data; expect government procurement to outline payment on delivery or milestone-based terms in full tender docs.
